Inclusion Criteria:

- Adult patients, >=18 years of age

- Acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia in
blast phase, refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma

- Relapsed or refractory to approved therapies, or no viable alternative therapy
available

- ECOG performance status of 0-2

Exclusion Criteria:

- Patients receiving any other agent or therapy to treat their malignancy

- Pre-existing gastrointestinal disorders which may interfere with absorption of drugs

- Clinically significant cardiovascular disease

- Pregnant or lactating women

- HIV-positive patients receiving combination antiretroviral therapy

- Amendment J and onward for patients in the food effect evaluation and for all
subsequent patients if dosing with a high fat/high calorie meal is found to be
optimal: Patients with allergies to any ingredient in the defined liquid supplement
and/or inability to tolerate a high fat/high calorie meal twice daily on scheduled
RO5045337 dosing days